Efficacy and Safety of Leuprolide Acetate 3-Month Depot 11.25 Milligrams or 30 Milligrams for the Treatment of Central Precocious Puberty
Authors:
- 1 May 2012
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 97 (5) , 1572-1580
Abstract
Context: GnRH agonist (GnRHa) monthly injections are frequently used in the treatment of central precocious puberty (CPP). The 3-month leuprolide depot 11.25- and 30-mg formulations are newly approved treatment options. Objective: The aim of the study was to investigate the safety and efficacy of leuprolide acetate 3-month depot formulations for the treatment of CPP in children. Design: This was a phase III, randomized, open-label, dose-ranging 6-month study. Setting: Twenty-two U. S. medical centers (including Puerto Rico) participated. Patients: Children diagnosed with CPP (n = 84), who were either treatment naive or previously treated with GnRHa, were recruited. Chronological age at onset of pubertal signs was less than 8 yr in girls and less than 9 yr in boys, and bone age was advanced over chronological age at least 1 yr. Intervention: Leuprolide acetate depot (11.25 or 30 mg) was administered im every 3 months. Main Outcome Measures: Biochemical [peak-stimulated LH, estradiol (girls), and testosterone (boys)] and anthropometric (growth rate, bone age acceleration, pubertal progression) parameters and safety were assessed. Results: Peak-stimulated LH was suppressed in the 11.25- and 30-mg dose groups in 78.4 and 95.2%, respectively, of children from months 2 through 6. There were nine treatment failures (peak-stimulated LH >4 IU/liter) in the 11.25-mg group and two in the 30-mg group. Basal sex steroid suppression, growth rates, pubertal progression, bone age advancement, and adverse events were similar with either dose. Conclusions: Treatment with leuprolide acetate 3-month depot formulations (11.25 and 30 mg) effectively suppressed the GnRH axis, was well tolerated, and may positively impact patient convenience and compliance. (J Clin Endocrinol Metab 97: 1572-1580, 2012)Keywords
This publication has 13 references indexed in Scilit:
- Efficacy of Leuprolide Acetate 1-Month Depot for Central Precocious Puberty (CPP): Growth Outcomes During a Prospective, Longitudinal StudyInternational Journal of Pediatric Endocrinology, 2011
- Leuprolide Acetate 1-Month Depot for Central Precocious Puberty: Hormonal Suppression and RecoveryInternational Journal of Pediatric Endocrinology, 2010
- Comparison of three doses of leuprolide acetate in the treatment of central precocious puberty: preliminary resultsClinical Endocrinology, 2009
- Adequacy of a Single Unstimulated Luteinizing Hormone Level to Diagnose Central Precocious Puberty in GirlsPediatrics, 2009
- The use of GnRH agonists in precocious pubertyEuropean Journal of Endocrinology, 2008
- Efficacy of a Monthly Compared to 3-Monthly Depot GnRH Analogue (Goserelin) in the Treatment of Children with Central Precocious PubertyHormone Research in Paediatrics, 2007
- Sequential Comparisons of One-Month and Three-Month Depot Leuprolide Regimens in Central Precocious PubertyThe Journal of Clinical Endocrinology & Metabolism, 2006
- Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious pubertyEuropean Journal of Endocrinology, 2006
- Precocious puberty and statural growthHuman Reproduction Update, 2004
- Treatment of Central Precocious Puberty by Subcutaneous Injections of Leuprorelin 3-Month Depot (11.25 mg)The Journal of Clinical Endocrinology & Metabolism, 2002